Department of Obstetrics and Gynecology, Kayseri City Training and Research Hospital, Kayseri, Turkey.
Eur Rev Med Pharmacol Sci. 2023 Apr;27(8):3519-3525. doi: 10.26355/eurrev_202304_32125.
This study aimed to compare serum PNX-14 values of women with PCOS classified as lean or overweight according to the BMI values.
Fifty lean or overweight women diagnosed with PCOS according to the revised Rotterdam criteria were included in the study. They were divided into two groups according to their BMI values. Thirty patients with BMI values of 18.5-24.9 kg/m2 constituted the normal-weight PCOS group. Twenty patients with BMI values of 25-29.9 kg/m2 formed the overweight PCOS group. Thirty patients with regular menstrual cycles who did not exhibit clinical and laboratory findings of PCOS were selected as the control group. The patients in the control group were also divided into two different groups as normal weight (n=17) and overweight (n=13). In anovulatory PCOS group, blood samples were collected on the third day of progesterone withdrawal bleeding. Both in ovulatory PCOS and control groups, blood samples were collected on the third day of spontaneous menstrual cycle. In addition to basal hormonal parameters, serum phoenixin-14 concentrations were measured by enzyme-linked immunosorbent assay.
LH values of the overweight or lean PCOS group were significantly higher than the overweight or lean non-PCOS group (p<0.01). The LH/FSH ratios of the lean and obese PCOS groups were significantly higher than the non-PCOS control group (p<0.01). Testosterone levels of both lean and obese PCOS groups were significantly higher than non-PCOS groups (p<0.02). The HOMA-IR value of the obese PCOS group was significantly higher than the lean PCOS group (p<0.03). The HOMA-IR values of the patients in the PCOS group were significantly higher than the non-PCOS controls. Phoenixin-14 levels of the obese PCOS group were approximately three times higher than the lean PCOS group (p<0.01). Phoenixin-14 levels of the obese non-PCOS group were also three times higher than the lean non-PCOS group (p<0.01). Serum Phoenixin-14 levels of patients in the lean PCOS group were significantly higher than in the lean non-PCOS group (9.11±2.09 pg/mL vs. 2.04±0.11 pg/mL, p<0.01). Serum Phoenixin-14 levels of the patients in the obese PCOS group were significantly higher than in the obese non-PCOS group (27.4±3.04 pg/mL vs. 6.44±1.09 pg/mL, p<0.01). A positive and significant correlation was found between serum PNX-14 levels and BMI, HOMA-IR, LH, and testosterone levels in both lean and obese PCOS patients.
This study showed for the first time that serum PNX-14 levels are significantly increased in lean and obese PCOS patients. The increase in PNX-14 showed a proportional trend with BMI levels. Serum PNX-14 levels were correlated positively with serum LH, testosterone, and HOMA-IR.
本研究旨在比较根据 BMI 值将多囊卵巢综合征（PCOS）患者分为瘦或超重的人群的血清 PNX-14 值。
本研究纳入了 50 名根据修订的鹿特丹标准被诊断为 PCOS 的瘦或超重女性。根据 BMI 值将她们分为两组。30 名 BMI 值为 18.5-24.9kg/m2 的患者构成正常体重 PCOS 组。20 名 BMI 值为 25-29.9kg/m2 的患者构成超重 PCOS 组。选择 30 名月经周期规律且无 PCOS 临床和实验室表现的患者作为对照组。对照组患者也分为正常体重组（n=17）和超重组（n=13）。在无排卵性 PCOS 组中，在孕激素撤退出血的第 3 天采集血样。在有排卵的 PCOS 组和对照组中，在自发性月经周期的第 3 天采集血样。除了基础激素参数外，还通过酶联免疫吸附试验测量血清凤凰素-14 浓度。
超重或瘦的 PCOS 组的 LH 值明显高于超重或瘦的非 PCOS 组（p<0.01）。瘦和肥胖 PCOS 组的 LH/FSH 比值明显高于非 PCOS 对照组（p<0.01）。两组瘦和肥胖 PCOS 组的睾酮水平均明显高于非 PCOS 组（p<0.02）。肥胖 PCOS 组的 HOMA-IR 值明显高于瘦 PCOS 组（p<0.03）。PCOS 组患者的 HOMA-IR 值明显高于非 PCOS 对照组。肥胖 PCOS 组的凤凰素-14 水平约为瘦 PCOS 组的三倍（p<0.01）。肥胖非 PCOS 组的凤凰素-14 水平也为瘦非 PCOS 组的三倍（p<0.01）。瘦 PCOS 组患者的血清凤凰素-14 水平明显高于瘦非 PCOS 组（9.11±2.09pg/mL 比 2.04±0.11pg/mL，p<0.01）。肥胖 PCOS 组患者的血清凤凰素-14 水平明显高于肥胖非 PCOS 组（27.4±3.04pg/mL 比 6.44±1.09pg/mL，p<0.01）。在瘦和肥胖的 PCOS 患者中，血清 PNX-14 水平与 BMI、HOMA-IR、LH 和睾酮水平呈正相关且显著相关。
本研究首次表明，瘦和肥胖的 PCOS 患者的血清 PNX-14 水平明显升高。PNX-14 的增加与 BMI 水平呈比例趋势。血清 PNX-14 水平与血清 LH、睾酮和 HOMA-IR 呈正相关。
